Do you want to read an article? Please log in or register.
Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry
Inflammatory Bowel Disease
Indications
Related content
Inflammatory Bowel Disease
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry
United European Gastroenterol J
Mañosa M, Calafat M, Ricart E, Nos P, Iglesias E, Riestra S, Mesonero F, Calvo M, Guardiola J, Hernández V, Rivero M, Carpio D, Mínguez M, Alba C, Martín-Arranz MD, Vela M, Gomollón F, García-López S, Casbas AG, Calvet X, González-Muñoza C, Barrio J, Gisbert JP, Sicilia B, Pérez-Calle JL, Bujanda L, Esteve M, Ramos L, Varela P, Sierra M, Merino O, Bermejo F, Acosta MB, Perez AR, Márquez-Mosquera L, García-Bosch O, Rodríguez-Lago I, Lorente Poyatos RH, García Sepulcre MF, Maroto N, Vega P, Monfort D, San Martín LZ, Busquets D, Martinez-Montiel P, Riera J, Alcain G, Llaó J, Marin N, Marin-Jimenez I, Sesé E, Van Domselaar M, Huguet JM, Ginard D, Bas-Cutrina F, Ber Y, Roncero O, Lucendo AJ, López-García A, Menacho M, Almela P, Ponferrada Á, Coronel AF, Maestro S, de Jesús Martínez-Pérez T, Vilafranca CM, Argüelles F, Legido J, Gilabert P, Charro M, Trapero AM, Fernández H, Frago S, Villalba LH, Muñoz E, Domènech E, ENEIDA registry of GETECCU
doi: 10.1002/ueg2.70150
Inflammatory Bowel Disease
Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study
Clin Gastroenterol Hepatol
Louis E, Sebastian S, Siegmund B, Bossuyt P, Danese S, de Boer N, Loftus EV, Moum B, Peyrin-Biroulet L, Schreiber S, Zhou J, Angellotti E, Adsul S, Jones S, Siegel CA
doi: 10.1016/j.cgh.2025.10.006
Inflammatory Bowel Disease
Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry
J Crohns Colitis
Pérez-Galindo P, Gisbert JP, Carrillo-Palau M, Bertoletti F, González-Vivó M, Pajares R, Merino O, Ferrer JÁ, Castaño A, Chaparro M, Calvo M, Barreiro-de Acosta M, Lorente RH, Algaba A, Madero-Velázquez L, Vela M, de la Maza S, Llaó J, Vega P, Utrilla A, Almela P, Domènech E, Carpio D, ENEIDA Registry of GETECCU
doi: 10.1093/ecco-jcc/jjag024
Inflammatory Bowel Disease
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
Lancet Gastroenterol Hepatol
Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ, COSTA Study Group
doi: 10.1016/S2468-1253(25)00291-2
Inflammatory Bowel Disease
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Lancet Gastroenterol Hepatol
Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group
doi: 10.1016/S2468-1253(25)00198-0
Inflammatory Bowel Disease
Trends in Use of Prescribed Opioids in Incident and Prevalent Patients With Ulcerative Colitis: A Nationwide Study in Sweden
Inflamm Bowel Dis
Osooli M, Voghera S, Bruze G, Nordenvall C, Hedin CRH, Everhov ÅH, Myrelid P, Ludvigsson JF, Olén O, SWIBREG Study Group§
doi: 10.1093/ibd/izaf278
Inflammatory Bowel Disease
Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study
J Crohns Colitis
D'Amico F, Fanizzi F, Dal Buono A, Gabbiadini R, Nardone OM, Zilli A, Allocca M, Lauriola GM, Jairath V, Peyrin-Biroulet L, Fiorino G, Castiglione F, Massimino L, Mastronardi M, Armuzzi A, Danese S
doi: 10.1093/ecco-jcc/jjag062
Inflammatory Bowel Disease
Placebo rates in randomised clinical trials of ulcerative colitis: An individual patient data meta-analysis
J Crohns Colitis
Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Vuyyuru S, Macdonald JK, Zou G, Yuan Y, Sands BE, Panaccione R, Feagan BG, Hanzel J, Sedano R, Dulai P, Narula N, Ma C, Jairath V
doi: 10.1093/ecco-jcc/jjaf191
Inflammatory Bowel Disease
Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: results of the cross-sectional CARUC-ASA study by the Belgian IBD Research and Development Group
J Crohns Colitis
Reenaers C, Lambrecht G, Pouillon L, Baert F, Cremer A, Colard A, Claessens C, Billiet T, Geldof J, De Zutter A, Rahier JF, Somers M, Reynders D, Vansteenkiste L, Arijs I, Louis E, Belgian IBD Research and Development Group (BIRD), Verstockt B
doi: 10.1093/ecco-jcc/jjag100